Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 13/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.41 |
| ▸ | ABL1 | P00519 | 8/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214702 | 0.87 | FGFR4 (0.51) | KDRBRAFABL1MAPK14BCR | |
| SCHEMBL19316721 | 0.86 | DDR2 (0.48) | KDRBRAFDDR2NTRK1NTRK3 | |
| SCHEMBL20214681 | 0.86 | MAPK14 (0.44) | KDRBRAFABL1LCKMAPK14 | |
| SCHEMBL20214668 | 0.84 | ABL1 (0.50) | KDRBRAFABL1MAPK14 | |
| SCHEMBL20214669 | 0.84 | ABL1 (0.50) | KDRBRAFABL1MAPK14 | |
| SCHEMBL20214756 | 0.84 | ABL1 (0.50) | KDRBRAFABL1MAPK14 | |
| SCHEMBL20214708 | 0.81 | ABL1 (0.45) | KDRBRAFABL1LCKMAPK14 | |
| SCHEMBL20214710 | 0.81 | EGFR (0.55) | KDRBRAFABL1MAPK14BCR | |
| SCHEMBL19316717 | 0.81 | KDR (0.49) | KDRBRAFDDR2NTRK1NTRK3 | |
| SCHEMBL21330457 | 0.81 | EGFR (0.52) | KDRBRAFABL1MAPK14BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | KDR 3965/4885BRAF 1396/4885DDR2 1488/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | KDR 3965/4885BRAF 1396/4885DDR2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.